aTyr Pharma, Inc. (ATYR) Securities Class Action Lawsuit

Shamis & Gentile, P.A. reminds investors of the upcoming lead plaintiff deadline of December 8, 2025 in the class action filed on behalf of investors who purchased or otherwise acquired aTyr Pharma, Inc. ("aTyr Pharma" or the "Company") (ATYR) securities between November 7, 2024 and September 12, 2025 (the "Class Period").

Investors suffering losses in excess of $50,000 are advised to contact the firm now for more information on how to participate.

In January 2025, aTyr Pharma highlighted its Phase 3 EFZO-FIT trial of efzofitimod for pulmonary sarcoidosis, expressing confidence in the drug’s safety and ability to reduce or eliminate steroid use. However, on September 15, 2025, the Company announced that the study failed to meet its primary efficacy endpoint, revealing that the placebo group performed better than expected despite limited secondary improvements.

On this news, shares of aTyr Pharma fell from a closing price of $6.03 on September 12, 2025, to $1.02 per share on September 15, 2025. This decline resulted in significant losses for investors and a substantial reduction in the Company's market capitalization.

The lawsuit filed after these events alleges that defendants made false and misleading statements and failed to disclose that: (1) aTyr’s Pharma EFZO-FIT study design created the false impression that efzofitimod would meet its primary endpoint; (2) the Company misrepresented that the trial would enable patients to fully discontinue steroid use; (3) aTyr Pharma did not disclose that other factors could account for steroid withdrawal; (4) the EFZO-FIT trial ultimately failed to meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48; and (5) as a result, the Company's statements misled investors about efzofitimod’s efficacy and the likelihood of achieving the primary endpoint.

If you purchased or otherwise acquired aTyr Pharma securities during the Class Period, you may move the Court no later than December 8, 2025 to request appointment as lead plaintiff in this putative class action lawsuit.

Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.